Defining prospective pathways by which zoonoses evolve and emerge as human pathogens is critical for anticipating and controlling both natural and deliberate pandemics. However, predicting tenable pathways of animal-to-human movement has been hindered by challenges in identifying reservoir species, cultivating zoonotic organisms in culture, and isolating full-length genomes for cloning and genetic studies. The ability to design and recover pathogens reconstituted from synthesized cDNAs has the potential to overcome these obstacles by allowing studies of replication and pathogenesis without identification of reservoir species or cultivation of primary isolates. Here, we report the design, synthesis, and recovery of the largest synthetic replicating life form, a 29.7-kb bat severe acute respiratory syndrome (SARS)-like coronavirus (Bat-SCoV), a likely progenitor to the SARS-CoV epidemic. To test a possible route of emergence from the noncultivable Bat-SCoV to human SARS-CoV, we designed a consensus Bat-SCoV genome and replaced the Bat-SCoV Spike receptor-binding domain (RBD) with the SARS-CoV RBD (Bat-SRBD). Bat-SRBD was infectious in cell culture and in mice and was efficiently neutralized by antibodies specific for both bat and human CoV Spike proteins. Rational design, synthesis, and recovery of hypothetical recombinant viruses can be used to investigate mechanisms of transspecies movement of zoonoses and has great potential to aid in rapid public health responses to known or predicted emerging microbial threats.
mergence of zoonotic-human pathogens is increasingly recognized as a threat to public health (1) . Human population growth and environmental changes have created new opportunities for contact between humans and zoonotic organisms that may result in cross-species transmission and human disease (1, 2) . Recent examples include RNA viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola, Hanta, Nipah, and Chikungunya viruses (2) . However, the determinants regulating successful transspecies movement remain poorly understood due to challenges in identifying viral precursors and animal reservoirs, thereby complicating vaccine and therapeutic design (3). SARS-CoV, which exemplifies the challenges inherent in studying emerging pathogens, was the first 21st century emerging virus to exhibit efficient human-to-human transmission and rapid global spread (4) (5) (6) . Although zoonotic SARS-CoV strains were isolated from civets and raccoon dogs (7) (8) (9) , the epidemic likely originated from strains circulating in bats (Bat-SCoVs) (10) (11) (12) . Bat CoVs cluster in both major mammalian CoV taxonomic groups, raising the possibility that Bat CoVs may be progenitors to all 4 known pathogenic human CoVs (11, 13) . Bats are also predicted to function as reservoirs for other important emerging human and animal viruses (14, 15) . Although several complete Bat CoV genome sequences are available, no Bat CoV has been successfully cultivated in cell culture or in animals (11, 13) , severely limiting the identification of determinants of zoonotic CoV transspecies movement.
The SARS-CoV Spike is a 180-kDa type I membrane glycoprotein that contains a well-defined receptor-binding domain (RBD).
The SARS-CoV genome is likely a mosaic of sequences derived from multiple recombination events, although this hypothesis is somewhat controversial (16) . However, recombination within Spike has been described often (17) , suggesting that the RBDs may be interchangeable between strains (18) (19) (20) . During the SARS-CoV outbreak, evolution in the Spike RBD allowed for more efficient use of human angiotensin-converting enzyme 2 (hACE2) as a receptor for entry (21, 22) . Because future zoonoses are likely, it is critical to identify strategies used by viruses to adapt in human populations. In this study, we have combined phylogenetic and bioinformatics analyses, large-scale cDNA synthesis, chimeric gene design, and reverse genetics to generate a consensus Bat-SCoV. Successful recovery of the infectious chimeric virus, Bat-SRBD, which includes the RBD within Spike from human SARS-CoV, demonstrates the plasticity of the CoV type I glycoprotein. The synthetic reconstruction and recovery of this novel chimeric virus identifies a necessary genetic element for CoV cross-species transmission, establishes a model system for testing experimental evolution of zoonotic CoVs, and allows for testing of vaccine and therapeutics against possible future zoonotic strains.
Results
Consensus Bat-SCoV Sequence Design and Construction. When this study was initiated, 4 Bat-SCoVs had been identified (HKU3-1, HKU3-2, HKU3-3, and RP3) as the virus reservoir populations from which SARS-CoV emerged (10) (11) (12) . Because none had been recovered in culture, the infectivity of the reported viral genomic RNA sequences was hypothetical, having been derived from RT-PCR sequencing of bat fecal or rectal swab samples. Sequence databases have error frequencies from 1/500 to 1/10,000, making viable genome reconstruction problematic with increasing size (23) . Therefore, we used the 4 reported Bat-SCoV sequences to establish a putative consensus Bat-SCoV sequence (GenBank accession no. FJ211859) and designed cDNA fragments with junctions precisely aligned to the existing SARS-CoV reverse genetics system [ Fig. 1A ; supporting information (SI) Fig. S1 ] (24) . The defined and functional SARS-CoV 5Ј UTR and transcriptional regulatory sequences were used because the 5Ј UTRs of the Bat-SCoVs were incomplete. The genomic cDNA fragments were commercially synthesized, inserted into vectors, assembled into a full-length cDNA, and transcribed in vitro to yield genomic RNA. Initial attempts to recover and passage infectious Bat-SCoV failed. Electroporated cells contained high levels of genome and leader-containing subgenomic transcripts on day 2, but not day 5 postelectroporation (p.e.) (Fig. 1C) , indicating that the synthetic consensus Bat-SCoV genome expressed a functional replicase. We did recover infectious virus consisting of SARS-CoV genome fragments A-E and Bat fragment F ( Fig. 1 B and D) . The resulting virus, Bat-F, encoded a chimeric Spike. Thus, the amino-terminal two-thirds of SARS-CoV Spike, including the RBD, and the fusion core contained within the carboxyl-terminal third of Bat-SCoV Spike can successfully drive productive infection. Also, because Bat-F contained Bat-SCoV accessory and structural genes 3Ј to the Spike gene, these downstream ORFs are clearly interchangeable.
Generation and Recovery of Chimeric Bat-SRBD. The ectodomain of Spike can be exchanged among CoVs, altering host-range specificity (25, 26) . To test whether the RBDs of Bat-SCoV and SARSCoV were interchangeable, we replaced the Bat-SCoV RBD (amino acid 323-505) with the SARS-CoV RBD (amino acid 319-518) (27, 28) (GenBank accession no. FJ211860), simulating a theoretical recombination event that might occur during mixed infection in vivo (Fig. 1B) . After electroporation, Bat-SRBD genome RNA and leader-containing subgenomic mRNA transcripts were detected (Fig. 1C) , and progeny virions were detected by plaque assay. After 2 additional passages, the population genome sequence was identical to the Bat-SRBD molecular clone. However, 4 nucleotides exhibited dual peaks on the sequencing electropherograms, suggesting quasispecies variation at these positions (Table S1 ). Recovery and passage of Bat-SRBD demonstrated the functional interchangeability of human and animal SARS-CoV-like RBDs.
The crystal structure of SARS-CoV RBD complexed with its receptor, hACE2 (29) , implicated 13 residues within the carboxyl terminus of the RBD (amino acid 426R-518D) in ACE2 engagement. Homology modeling indicated that this receptor-binding motif (RBM) may be sufficient to allow ACE2 engagement, and further predicts that inclusion of 6 residues amino-terminal to the RBM (amino acid 388V-393D) may enhance ACE2 engagement by functioning as a distal ''hinge.'' To test this possibility, chimeric Bat-SCoV genomes were constructed containing either the SARSCoV RBM (Bat-SRBM) or the RBM plus the distal hinge residues (Bat-Hinge) (Fig. 1B) . Electroporation yielded genome and subgenomic leader-containing transcripts at day 2, but not 5, p.e. (Fig.  1 C and D) , and progeny virions could not be successfully passaged in culture.
Virus Replication in Primate and Murine Cells. We next infected Vero cells, murine delayed brain tumor (DBT) cells, and DBT cells expressing hACE2 or civet (c)ACE2 (DBT-hACE2 and DBTcACE2) (22) with Bat-SRBD or SARS-CoV at a multiplicity of infection (MOI) of 0.01 or 1 plaque forming unit (PFU) per cell (Fig. 2) . Bat-SRBD and SARS-CoV exhibited productive growth in Vero, DBT-hACE2, and DBT-cACE2 cells that was remarkably similar in kinetics and peak titers (Fig. 2) . In contrast, DBT cells lacking ACE2 expression did not support growth of either SARSCoV or Bat-SRBD (data not shown). These data indicate that Bat-SCoV expressing the SARS-CoV RBD is capable of entering cells by using ACE2 from humans, nonhuman primates, or civets as receptor, and replicating efficiently.
Detection of Bat-SRBD Replicase Proteins by SARS-CoV Antibodies.
Comparison of SARS-CoV and Bat-SRBD predicted high, but not complete, identity of amino acid sequences across replicase proteins (Table S2 ). Because antibody cross-reactivity is a potential tool for detection and analysis of Bat-SCoVs, we tested whether antibodies specific for SARS-CoV proteins (30) could also detect Bat-SRBD homologues. Immunoblots were performed by using rabbit polyclonal antibodies (pAbs) specific for SARS-CoV nsp1, nsp8, nsp9, Neutralization of Bat-SRBD. To examine antigenic relatedness, the Bat-SCoV Spike was cloned into Venezuelan Equine Encephalitis viral replicon particle (VRP) vectors, and pools of mouse (m)pAbs were tested for neutralization of Bat-SRBD infectivity. All BatSCoV Spike-specific sera efficiently neutralized Bat-SRBD, with 50% neutralization titers ranging from 1/100 to 1/400 dilutions (Fig.  3A) . In parallel, these sera did not neutralize SARS-CoV infectivity, suggesting that the antibodies recognize epitopes in Spike outside the RBD in Bat-SRBD. Because the RBD appears to be the minimal motif required to alter host range of the Bat-SCoV precursor, we also tested whether Bat-SRBD could be neutralized with human monoclonal antibodies (hmAbs S109.8, S227.14, and S230.15), which recognize unique epitopes within the SARS-CoV RBD and cross-neutralize human and zoonotic SARS-CoV isolates in vitro and in vivo (31) . The hmAbs neutralized Bat-SRBD, demonstrating the accessibility of the neutralizing epitopes of SRBD in the background of the Bat-SCoV Spike (Fig. 3B ). Neutralization also functions as an important safety feature in design and study of Bat-SRBD viruses.
Bat-SRBD Replicates in Human Airway Epithelial (HAE) Cell Cultures.
Because Bat-SRBD grew equivalently to SARS-CoV in culture, we tested whether Bat-SRBD could replicate in primary HAEs, which recapitulate the epithelium of the human conducting airway. We have previously identified zoonotic SARS-CoV variants that replicated efficiently in Vero cells, but not in HAE cultures (22, 32) . Therefore, HAE cultures provide a more relevant and stringent measure of the replicative potential of chimeric recombinant zoonotic SARS-CoV viruses in the human host. HAE cultures were inoculated by means of the apical surface and the media sampled at different times postinfection (p.i.). Peak titers of SARS-CoV and Bat-SRBD were similar, although Bat-SRBD growth was delayed, compared with SARS-CoV (Fig. 4A) . Because hACE2 is detected primarily on the apical surface of ciliated cells in HAEs (33), we looked for differences in targeting of Bat-SRBD and SARS-CoV infection in HAEs. Histological sections from HAE at 144-h p.i. were probed with Spike-specific antisera, and localization assessed by indirect immunofluorescence. For both viruses, Spike was detected predominantly on the apical surface of ciliated cells (Fig.  4 B and C) , but was not detected in nonciliated cells. hypothesis that Y436H enhances interaction with mACE2, Bat-SRBD was constructed with this substitution (Bat-SRBD-MA). Electroporation with Bat-SRBD-MA genome RNA resulted in production of infectious virus with titers similar to Bat-SRBD (Fig.   1B) . Next, 14-month-old BALB/c mice were infected with Bat-SRBD, Bat-SRBD-MA, or SARS-CoV. Mice were weighed and monitored daily for morbidity, and on days 2 and 4 p.i., mice were euthanized and lungs harvested (Fig. 5 ). Mice infected with chimeric viruses did not exhibit significant weight loss or morbidity after infection (Fig. 5A) . However, although Bat-SRBD replicated in infected lungs, Bat-SRBD-MA replicated Ϸ1.5 logs more efficiently at day 2 ( Fig. 5B) , providing support for the hypothesis that the Y436H substitution in Bat-SRBD-MA may improve mACE2 receptor engagement.
Discussion
Reverse genetic systems have revolutionized our understanding of the molecular basis of viral replication, pathogenesis, and vaccine design for many virus families. However, application of these technologies to emerging pathogens has been limited by factors involved in constructing and manipulating molecular clones and characterizing recombinant viruses, particularly those with large genomes. Also, standard approaches for development of infectious clones have required availability of viral RNA or DNA, and consequently have been mostly limited to viruses that replicate in culture. Last, classical approaches to combat emerging or deliberately introduced human pathogens may not allow responses in a timeframe adequate to significantly reduce mortality or morbidity. Thus, new methodologies to rapidly recover and test emerging zoonotic pathogens are critical. Recent studies have provided crucial steps toward the goal of synthetic reconstruction of large microbial genomes. The 7.5-and 5.6-kb genomes of poliovirus and X174, respectively, were reconstructed from known sequences by using commercially synthesized cDNA fragments and PCR assembly (37, 38) . Similarly, the segmented genome of the 1918 strain of influenza was reconstructed, in part, by using synthetic design (39) . Human endogenous retroviruses were assembled by PCR-directed assembly of synthetic oligonucleotides into a consensus provirus (40) , and recombinant SARS-CoVs bearing synthetic zoonotic Spike sequences were derived by our group (22, 32) . Last, the cloning of the 580-kb microbial genome of Mycoplasma genitalium was reported, although this work has not yet yielded a replicating organism (41) . To our knowledge, no studies to date have used a synthetic approach to assess potential mechanisms of zoonotic emergence of a noncultivable virus.
Because it is possible that even minor events of recombination and mutation-driven evolution can alter CoV population structure and promote emergence (22, 32, 42) , CoVs may select for alterations in discrete regions of Spike to achieve host-range expansion. The CoV Spike, a type I fusion protein, contains 2 discrete regions, a carboxyl-terminal S2 region that encodes fusion and heptad repeat domains in an arrangement shared by other viral attachment proteins possessing type I architecture (43) , whereas the S1 region encodes the RBD. Studies in our and other laboratories have identified mutations in both S1 and S2 regions associated with CoV host-range expansion (42, 44) . These 2 regions may also independently or cooperatively mediate transspecies expansion and neutralization escape, in that some mAbs that target the SARS-CoV S1 RBD select for escape mutants in the RBD, but also in the S2 region (45) . These data suggest that coordinated interactions between the S1 RBD and select S2 domains may be important in epitope presentation and Spike function.
We have identified several hmAbs that bind distinct, conserved locations in the SARS-CoV RBD and neutralize strains that originate from animal and human hosts (31) . These hmAbs did efficiently neutralize Bat-SRBD, an important finding as it was not previously clear that mAbs targeting the SARS-CoV RBD would neutralize virus in the context of a different Spike backbone. It is also informative that antibodies specific for the Bat-SCoV Spike protein neutralize Bat-SBRD, which expresses a chimeric Spike protein, but not SARS-CoV, indicating the existence of neutralizing antibodies that target portions of Spike outside the RBD. Importantly, these results suggest that hmAbs specific for SARS-CoV, and by inference the current panel of SARS-CoV vaccines, may provide significant protection against other SARS-like CoVs that emerge from zoonotic pools by natural recombination or are deliberately designed to cross species. Second, both SARS-CoV RBD-specific hmAbs and Bat-SCoV mpAbs specific for Spike epitopes outside of the RBD are able to recognize and neutralize virus even in the setting of a chimeric Spike, providing important safety features for studies of emerging zoonotic CoVs.
It has been shown that the 5Ј UTRs of CoVs can influence the capacity of the virus to replicate in cells (46) . Although the 5Ј UTR in the synthetic Bat-SCoV originated from SARS-CoV, the sole difference between Bat-SCoV, which was not capable of amplification in cell culture, and Bat-SRBD, which could be recovered, was the RBD derived from SARS-CoV. Our results also confirm and extend a previous report predicting that deletions and mutations within the Bat-SCoV RBM ablate interaction with hACE2 and cACE2 molecules (47) . Thus, in this report, we show that the CoV Spike RBD is interchangeable, is sufficient to confer efficient growth and infectivity in cells from multiple species, and likely represents a critical determinant of transspecies movement of zoonotic CoVs.
To protect against future emerging zoonotic pathogens, it is crucial to develop cell culture and animal models to test vaccines and therapeutics, ideally against entire families of organisms, such as CoVs. Both SARS-CoV and Bat-SRBD replicated efficiently in HAE cultures, providing a direct human airway model for comparison of existing and new antivirals. However, Bat-SRBD replicated poorly in vivo, calling for additional modifications to facilitate studies in mouse models. Robust structural information exists on the RBD-ACE2 interaction (29) , mutations affecting this interaction have been identified (22, 31) , and Rosetta-modeling of short range RBD-mACE2 receptor interfaces can identify key residues essential for retargeting the host specificity of Bat-SRBD (Fig. S3 ) (48) . Previous studies had identified a mutation in the RBD of the MA15 strain, Y436H, but its exact role in vivo was not clear (36) . By using structural modeling algorithms, we predicted that the Y436H substitution would enhance the interaction of Bat-SRBD with mACE2. Bat-SRBD-MA did exhibit increased growth efficiency in aged mice. However, this did not result in clinical disease, suggesting the requirement for additional adaptive changes. For example, SARS-CoV encodes at least 5 IFN antagonists, predicted to function in virulence (49) (50) (51) (52) . Our model system will allow mapping of the domains in the Bat-SCoV and SARS-CoV genetic backgrounds involved in regulation of virulence in aged animals.
In this report, sequence and structural information was integrated with synthetic genomics, reverse genetics, and protein design to recover a zoonotic precursor virus from a hypothetical infectious sequence. The resulting chimera exhibited cross-reactivity with previously identified therapeutics and highlighted possible previously undescribed mechanisms for host-range expansion. Here, we articulate a model to predict and directly test tenable emergence pathways. Paired with a greater availability of reagents and therapeutics, our studies represent an approach for rapid recovery and testing of newly identified pathogens, and which may improve public health preparedness and intervention strategies against natural or intentional zoonotic-human epidemics.
Materials and Methods
Cells and Viruses. VeroE6 cells (Vero) were maintained in MEM (Invitrogen), and delayed brain tumor (DBT, murine astrocytoma) cells were maintained in Dulbecco's MEM (Invitrogen) containing 10% FBS. DBT-hACE2 and DBT-cACE2 cells were cultured as described (22) . HAE cells were plated and differentiated as described (33) . SARS-CoV Urbani strain (hereafter, SARS-CoV) and Bat-SCoV wild type and chimeric viruses were propagated and assessed by plaque assay on Vero cells. All studies with viable SARS-CoV and SARS-CoV-like viruses were performed in certified BSL3 laboratories in biological safety cabinets, by using safety protocols that were reviewed and approved by the Institutional Biosafety Committees of Vanderbilt University and the University of North Carolina at Chapel Hill.
Determining the Consensus Sequence for Synthetic Bat-SCoV and Conceptual
Design of the Bat-SCoV Clone. HKU3-1 (DQ022305), HKU3-2 (DQ084200), HKU3-3 (DQ084199), and RP3 (DQ071615) genomes were aligned by using ClustalXv1.83 to determine a consensus sequence (Fig. S1 and Figs. S4 -S6) (GenBank accession no. FJ211859). The consensus Bat-SCoV sequence was designed to ligate interchangeably with the SARS-CoV infectious clone (24) . Notably, there was no consensus at the 5Јend of the Bat-SCoV genomes, so we used the 5Ј most region of SARS-CoV to append the T7 promoter site to the 5Ј end of the Bat-A fragment.
Construction of Chimeric Spike Variants.
Insertions of SARS-CoV sequence in place of Bat-SCoV sequence were engineered by using PCR and the primers shown in Table S3 . PCR amplicons for Bat-SRBD (GenBank accession no. FJ211860) and Bat-SRBM were generated by using fragments Bat-E2, and SARS-E. PCR amplicons for Bat-Hinge (Bat-SRBM plus 6 additional residues from SARS-CoV Spike) were generated by using Bat-SRBM as template. PCR-generated products were cloned into the Bat-E2 plasmid by using unique 5Ј-BstBI and 3Ј-MscI sites. Successful insertions of SARS-CoV sequence were confirmed by restriction digestion and nucleotide sequencing across the region of PCR amplification.
Generation of SARS-CoV and Bat-SCoV Mutant Viruses.
Viruses containing PCR-generated insertions within the viral coding sequence were produced by using the SARS-CoV assembly strategy (24, 33, 53) with the following modifications. Briefly, for Bat-F virus, full-length cDNA was constructed by ligating restriction products from SARS-CoV fragments A-E and Bat-SCoV fragment F, which required a BglI-NotI digestion. For Bat-SCoV and Bat-SRBD, Bat-SRBM, and Bat-Hinge, plasmids containing the 7 cDNA fragments of the Bat-SCoV genome were digested by using BglI for Bat-A, Bat-B, Bat-C, and Bat-D, BglI and AflII for Bat-E1 and Bat-E2, and BglI and NotI for Bat-F. Digested, gel-purified fragments were simultaneously ligated together. Transcription was driven by using a T7 mMessage mMachine kit (Ambion), and RNA was electroporated into Vero cells (24, 53) . Virus viability was determined by cytopathic effect and progeny viruses were passaged at low MOI. RNA was recovered from infected cell monolayers by using TRIzol (Invitrogen) according to the manufacturer's instructions, and genome origins were verified by RT-PCR and nucleotide sequencing.
Assay for Bat-SCoV Leader-Containing Transcripts in Electroporated Cells and Mouse Lungs. At days 2 and 5 p.e., generation of leader-containing N (ORF9) and genome (ORF1) transcripts was determined by RT-PCR. Briefly, RT-PCR was performed by using random hexamers (ABI) and SuperScript III (Invitrogen) to generate first-strand cDNA at an extension temperature of 55°C for 1 h. Leadercontaining cDNAs were amplified by PCR by using Taq with Thermopol buffer (NEB) and the following primers: 5Ј-CAGGAAAAGCCAACCAACCTTG (leader) and 5Ј-CGCTACGACCGAACTGAATGCC to detect Bat-SCoV genomic RNA; and leader and 5Ј-GTGAGAGCTGTGAACCAAGACG to detect mRNA 9 transcripts. Presence or absence of PCR products was assessed by electrophoresis on 1.5% agarose gels. Viral Growth and Plaque Assays. Vero, DBT, DBT-hACE2, or DBT-cACE2 cells were infected at a MOI of 1 or 0.01 PFU/cell. After 1 h at 37°C, the inocula were removed, cells were washed and samples were taken at different times p.i. To determine viral titer, samples were diluted, inoculated onto Vero cell monolayers in 6-well plates for 1 h, and overlaid with complete media plus 1% agar. Plaques were visualized between 48 and 52 h p.i. by neutral red staining (Sigma).
Generation of Polyclonal Bat-SCoV Spike-Specific Sera and Neutralization Assay. Murine pAbs specific for the Bat-SCoV Spike were generated as previously described (33) . Neutralizing titers for mpAbs and hmAbs S109.8, S227.14, and S230.15 were determined by plaque reduction neutralization titer assay (PRNT50%) (31) . The percentage of neutralization was calculated as follows: 1-(number of plaques in the presence of antibody/number of plaques in the absence of antibody) x 100%.
Infection of Aged BALB/c Mice. Ten each of aged (14 months) female BALB/c mice (National Institute of Aging) were lightly anesthetized and infected intranasally with 10 5 PFU of Bat-SRBD, Bat-SRBD-MA, or SARS-CoV; 5 additional mice were inoculated with an equivalent volume (50 L) of PBS. Mice were weighed daily through 4 days p.i., and on days 2 and 4 p.i., 5 mice of each group were killed and lungs harvested for determination of viral titer. Lungs were weighed and homogenized in 500 L of PBS at 6,000 rpm for 60 s in a MagnaLyser (Roche). Clarified homogenates were then diluted serially, and titers were determined by plaque assay on Vero cells.
